These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 38834487)

  • 1. GLP-1 receptor agonist tachyphylaxis and perioperative recommendations.
    Wu F; Klapman SA; Everett LL; Kuo B; Hobai IA
    Br J Anaesth; 2024 Aug; 133(2):437-438. PubMed ID: 38834487
    [No Abstract]   [Full Text] [Related]  

  • 2. Is it necessary to stop glucagon-like peptide-1 receptor agonists prior to endoscopic procedure? A retrospective study.
    Ghazanfar H; Javed N; Qasim A; Sosa F; Altaf F; Khan S; Mahasamudram J; Jyala A; Kandhi SD; Shin D; Mantri N; Sun H; Hanumanthu S; Patel H; Makker J; Balar B; Dev A; Chilimuri S
    World J Gastroenterol; 2024 Jul; 30(26):3221-3228. PubMed ID: 39086638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Point-of-Care Gastric Ultrasound to Identify a Full Stomach on a Diabetic Patient Taking a Glucagon-Like Peptide 1 Receptor Agonist.
    Girón-Arango L; Perlas A
    A A Pract; 2024 Feb; 18(2):e01751. PubMed ID: 38305719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perioperative management of long-acting glucagon-like peptide-1 (GLP-1) receptor agonists: concerns for delayed gastric emptying and pulmonary aspiration.
    van Zuylen ML; Siegelaar SE; Plummer MP; Deane AM; Hermanides J; Hulst AH
    Br J Anaesth; 2024 Apr; 132(4):644-648. PubMed ID: 38290907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
    Milder DA; Milder TY; Liang SS; Kam PCA
    Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantified Metrics of Gastric Emptying Delay by Glucagon-Like Peptide-1 Agonists: A Systematic Review and Meta-Analysis With Insights for Periprocedural Management.
    Hiramoto B; McCarty TR; Lodhia NA; Jenkins A; Elnaiem A; Muftah M; Flanagan R; Chan WW
    Am J Gastroenterol; 2024 Jun; 119(6):1126-1140. PubMed ID: 38634551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In reply: Comment on: Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
    Wu F; Klapman SA; Everett LL; Kuo B; Hobai IA
    Can J Anaesth; 2024 Aug; 71(8):1174. PubMed ID: 38872003
    [No Abstract]   [Full Text] [Related]  

  • 8. Retained Gastric Contents After Adequate Fasting Associated with GLP-1 Receptor Agonist Use: A Report of 3 Cases.
    Kittner SL; Talbott AL; Vishneski SR; Narbaiza J; Shields JS
    JBJS Case Connect; 2023 Oct; 13(4):. PubMed ID: 37943967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of glucagon-like peptide receptor 1 agonist therapy with the presence of gastric contents in fasting patients undergoing endoscopy under anesthesia care: a historical cohort study.
    Wu F; Smith MR; Mueller AL; Klapman SA; Everett LL; Houle T; Kuo B; Hobai IA
    Can J Anaesth; 2024 Jul; 71(7):958-966. PubMed ID: 38485835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1/glucagon receptor agonists in type 2 diabetes.
    De Block CEM; Dirinck E; Verhaegen A; Van Gaal LF
    Diabetes Obes Metab; 2022 May; 24(5):788-805. PubMed ID: 34984793
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Incidence of Pulmonary Aspiration During Upper Endoscopy in Patients Prescribed a Glucagon-Like Peptide 1 Receptor Agonist.
    Anazco D; Fansa S; Hurtado MD; Camilleri M; Acosta A
    Clin Gastroenterol Hepatol; 2024 Jun; 22(6):1333-1335.e2. PubMed ID: 38043694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review.
    Albèr A; Brønden A; Knop FK
    Diabetes Obes Metab; 2017 Jul; 19(7):915-925. PubMed ID: 28211611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adherence to NICE guidance on glucagon-like peptide-1 receptor agonists among patients with type 2 diabetes mellitus: an evaluation using the Clinical Practice Research Datalink.
    Jameson K; D'Oca K; Leigh P; Murray-Thomas T
    Curr Med Res Opin; 2016; 32(1):49-60. PubMed ID: 26428701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for Type 2 Diabetes Mellitus: What's Up and Coming in the Glucagon-Like Peptide-1 (GLP-1) Pipeline?
    Elder MJ; Ashjian EJ
    J Pharm Pract; 2023 Apr; 36(2):418-428. PubMed ID: 34620002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-Like Peptide-1 Receptor Agonist Use and Residual Gastric Content Before Anesthesia.
    Sen S; Potnuru PP; Hernandez N; Goehl C; Praestholm C; Sridhar S; Nwokolo OO
    JAMA Surg; 2024 Jun; 159(6):660-667. PubMed ID: 38446466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinically significant emesis in a patient taking a long-acting GLP-1 receptor agonist for weight loss.
    Weber M; Siddarthan I; Mack PF
    Br J Anaesth; 2023 Aug; 131(2):e37-e39. PubMed ID: 37302962
    [No Abstract]   [Full Text] [Related]  

  • 19. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect.
    Fisman EZ; Tenenbaum A
    Cardiovasc Diabetol; 2021 Nov; 20(1):225. PubMed ID: 34819089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of glucagon-like peptide-1 receptor-targeted imaging probe with in vivo glucagon-like peptide-1 receptor agonist glucose-lowering effects.
    Murakami T; Fujimoto H; Fujita N; Hamamatsu K; Yabe D; Inagaki N
    J Diabetes Investig; 2020 Nov; 11(6):1448-1456. PubMed ID: 32323451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.